Current guidelines on the diagnoses and management of cystic fibrosis (CF) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes. Increasing evidence supports treating early glucose abnormalities in cystic fibrosis patients to target CF specific outcomes, including lung function and nutrition (BMI-Body Mass Index). However, the criteria and timing of when to start insulin therapy in the 'prediabetic' state are unclear. A more accurate characterization of blood sugar variability in youth with and without CF will help the investigators better interpret continuous glucose monitor (CGM) findings in patients with CF prediabetes and diabetes and more accurately identify those individuals at greatest risk for disease progression.
Study Type
OBSERVATIONAL
Enrollment
146
Children's Hospital Colorado, University of Colorado Denver
Aurora, Colorado, United States
The percentage of time spent > 140 mg/dl on CGM
Percentage of time above normal glucose cut-point.
Time frame: 7 days
The percentage of time spent > 120 mg/dl on CGM
Measures of glucose variability on CGM
Time frame: 7 days
The percentage of time spent > 200 mg/dl on CGM
Measures of glucose variability on CGM
Time frame: 7 days
The percentage of time spent < 70 mg/dl on CGM
Measures of glucose variability on CGM
Time frame: 7 days
The percentage of time spent < 60 mg/dl on CGM
Measures of glucose variability on CGM
Time frame: 7 days
The number of excursions > 200mg/dl in 24 hours for one week
Measures of glucose variability including peak glucose, mean glucose and measures of glucose variability on CGM.
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.